INIS
comparative evaluations
12%
conversion
12%
creatine
12%
damage
12%
data
50%
doses
12%
drugs
12%
excretion
25%
genetics
12%
humans
37%
inhibition
50%
interference
50%
kidneys
25%
kinases
12%
lactate dehydrogenase
12%
lactates
25%
levels
12%
liver
87%
metabolism
12%
mice
12%
muscles
50%
oxalates
37%
phenotype
12%
plasma
12%
primates
12%
reviews
25%
rna
50%
therapy
12%
tissues
12%
Medicine and Dentistry
Adverse Event
12%
Chemotherapeutic Agent
12%
Combination Therapy
25%
Creatine Kinase
12%
Drug
12%
Excretion
12%
Family
12%
Genetic Disorder
12%
Glyoxylic Acid
25%
Kidney Injury
12%
Lactate Dehydrogenase
12%
LDHA
100%
Liver
37%
Metabolism
12%
Muscle
37%
Muscle Function
12%
Phenotype
12%
Placebo
25%
Plasma
12%
Primary Hyperoxaluria
50%
Pyruvate Kinase
12%
Pyruvic Acid
12%
RNA Interference
87%
RNAi Therapeutics
12%
Single Drug Dose
12%
Target Tissue
12%
Therapeutic Procedure
25%
Urinary Excretion
12%
Urinary System
12%
Biochemistry, Genetics and Molecular Biology
Creatine Kinase
12%
Electric Potential
12%
Excretion
12%
Genetic Disorder
12%
Human
25%
Lactate Blood Level
12%
Lactate Dehydrogenase
12%
LDHA
100%
Metabolic Pathway
12%
Mouse
12%
Muscle Function
12%
Normal Human
12%
Phenotype
12%
Primate
12%
Pyruvate Kinase
12%
Single Drug Dose
12%
Target Tissue
12%
Urinary Excretion
12%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
12%
Creatine Kinase
12%
Drug
12%
Genetic Disorder
12%
Glyoxylic Acid
25%
Human
25%
Kidney Injury
12%
Lactate Dehydrogenase
12%
Lactic Acid
25%
Mouse
12%
Normal Human
12%
Oxalate
37%
Oxalosis 1
50%
Pyruvate Kinase
12%
Pyruvic Acid
12%
Randomized Controlled Trial
37%